Research output per year
Research output per year
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Aberrations in circulating ceramide levels are associated with poor clinical outcomes across localised and metastatic prostate cancer
Lin, H. M., Huynh, K., Kohli, M., Tan, W., Azad, A. A., Yeung, N., Mahon, K. L., Mak, B., Sutherland, P. D., Shepherd, A., Mellett, N., Docanto, M., Giles, C., Centenera, M. M., Butler, L. M., Meikle, P. J. & Horvath, L. G., 2021, (Accepted/In press) In: Prostate Cancer and Prostatic Diseases.Research output: Contribution to journal › Article › peer-review
-
ELOVL5 is a critical and targetable fatty acid elongase in prostate cancer
Centenera, M. M., Scott, J. S., Machiels, J., Nassar, Z. D., Miller, D. C., Zinonos, I., Dehairs, J., Burvenich, I. J. G., Zadra, G., Chetta, P. M., Bango, C., Evergren, E., Ryan, N. K., Gillis, J. L., Mah, C. Y., Tieu, T., Hanson, A. R., Carelli, R., Bloch, K., Panagopoulos, V. & 13 others, , Apr 2021, In: Cancer Research. 81, 7, p. 1704-1718 15 p.Research output: Contribution to journal › Article › peer-review
1 Citation (Scopus) -
Synthesis and fluorine-18 radiolabeling of a phospholipid as a PET imaging agent for prostate cancer
Kwan, K. H., Burvenich, I. J. G., Centenera, M. M., Goh, Y. W., Rigopoulos, A., Dehairs, J., Swinnen, J. V., Raj, G. V., Hoy, A. J., Butler, L. M., Scott, A. M., White, J. M. & Ackermann, U., Feb 2021, In: Nuclear Medicine and Biology. 93, p. 37-45 9 p.Research output: Contribution to journal › Article › peer-review
-
Fatty acid oxidation is an adaptive survival pathway induced in prostate tumors by HSP90 inhibition
Nassar, Z. D., Mah, C. Y., Centenera, M. M., Irani, S., Sadowski, M. C., Scott, J. S., Nguyen, E. V., Nagarajan, S. R., Moldovan, M., Lynn, D. J., Daly, R. J., Hoy, A. J. & Butler, L. M., 1 Oct 2020, In: Molecular Cancer Research. 18, 10, p. 1500-1511 12 p.Research output: Contribution to journal › Article › peer-review
1 Citation (Scopus) -
Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: A study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)
Scheinberg, T., Kench, J., Stockler, M., Mahon, K. L., Sebastian, L., Stricker, P., Joshua, A. M., Woo, H., Thanigasalam, R., Ahmadi, N., Centenera, M. M., Butler, L. M. & Horvath, L. G., 26 Jan 2020, In: BMJ open. 10, 1, e033667.Research output: Contribution to journal › Article › peer-review
5 Citations (Scopus)